News & Events

Results of Operations and Financial Condition ​ A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1. ​ The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Other Events ​ A copy of the press release issued by Bio-Techne Corporation on May 6, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2. ​

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Officer Transition On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. In addition, the Compan…

Other Events ​ A copy of the press release issued by Bio-Techne Corporation on February 4, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2. ​

Results of Operations and Financial Condition ​ A copy of the press release issued by Bio-Techne Corporation on February 4, 2026, describing the results of operations for the quarter and six months ended December 31, 2025, and its financial condition as of December 31, 2025 is attached hereto as Exhibit 99.1. ​ The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…

Regulation FD Disclosure. On April 30, 2025, the Board of Directors of Bio-Techne Corporation (the “ Company ”) authorized a share repurchase program (the “ Share Repurchase Program ”), pursuant to which the Company may, from time to time, purchase shares of its common stock for an aggregate repurchase not to exceed a total of $500,000,000. This replaces the Company’s previous stock repurchase authorization approved by the Board on February 2, 2022. There is no time limit on the Share Repurch…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Quarterly Report of Bio-Techne Corporation (the “Company”) for the quarter ended September 30, 2024 and filed with the U.S. Securities and Exchange Commission on November 5, 2024, the expiration dates with respect to 794,400 shares subject to outstanding vested options held by former employees was under dispute. In 20…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2024, the Compensation Committee of the Board of Directors of Bio-Techne Corporation (the “Company”) granted James Hippel, the Company’s Executive Vice President, Chief Financial Officer, a one-time restricted stock unit award in the amount of 34,634 shares pursuant to the Company’s 2020 Equity Incentive Plan, as amended to date (the…